Stock comparison
Edwards Lifesciences
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
EW
Edwards Lifesciences
Market cap
$49.39B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | EW | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 61C | 77B | LMAT |
| Benjamin Graham | 89A | 89A | Tie |
| Philip Fisher | 62C | 81C | LMAT |
| Peter Lynch | 26F | 67B | LMAT |
| Joel Greenblatt | 54C | 56D | LMAT |
| Charlie Munger | 71C | 68D | EW |
| Terry Smith | 70B | 69D | EW |
Side-by-side metrics
| Metric | EW | LMAT |
|---|---|---|
| Market cap | $49.39B | $2.23B |
| P/E (TTM) | 43.2x | 37.1x |
| EV/EBIT | 27.6x | 36.6x |
| ROIC (TTM) | 12.06% | 9.43% |
| Gross margin | 78.01% | 72.39% |
| Net margin | 17.34% | 24.35% |
| Revenue CAGR 5y | 3.77% | 12.75% |
| EPS CAGR 5y | -6.52% | 19.04% |
| Debt / Equity | 0.1x | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
EW leads on
- Market cap$49.39Bvs $2.23B+95%
- Debt / Equity0.1xvs 0.5x+85%
- EV/EBIT27.6xvs 36.6x+24%
- ROIC (TTM)12.06%vs 9.43%+22%
LMAT leads on
- EPS CAGR 5y19.04%vs -6.52%+134%
- Dividend yield0.84%vs 0.0%+100%
- Revenue CAGR 5y12.75%vs 3.77%+70%
- Net margin24.35%vs 17.34%+29%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.